MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+5.96 (+10.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close55.54
Bid62.34 x 800
Ask62.40 x 1400
Day's Range56.56 - 61.65
52 Week Range11.54 - 87.00
Avg. Volume21,577,146
Market Cap22.83B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateAug 05, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bloomberg

    U.S. Cases Rise; Trump G-7 May Draw Fewer Leaders: Virus Update

    (Bloomberg) -- New York is targeting “hotspots” as New York City prepares to reopen in less than two weeks. U.S. cases increased 1.7%, faster than the one-week daily average.Attendance at a June U.S.-hosted meeting of world leaders could shrink because of the outbreak. Siemens Healthineers received U.S. emergency authorization for a coronavirus antibody test.European Union leaders urged the U.S. to reverse a decision to quit the World Health Organization. Italian cases trended lower as the government starts to allow travel, despite objections over letting people leave the hard-hit region near Milan.Key Developments:Virus Tracker: Cases top 6 million; deaths over 367,000Indonesia to open malls, entertainment sites as cases riseTexas shows the world how to reopen cautiously, for nowChinese vaccine expected to begin mass output soonRace to the freezer: Europe’s food glut has nowhere to goPizza chains have windfall on surge in takeout, deliveriesBaseball on ESPN: Korea’s major league plays through outbreakSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus. For a look back at this week’s top stories from QuickTake, click here.U.K., France Mull G-7 as Germany Skips (5 p.m. NY)The Covid-19 outbreak may deter German Chancellor Angela Merkel from attending a Group of Seven leaders meeting in the U.S., but other leaders are still in talks with the host, President Donald Trump.Trump spoke with French President Emmanuel Macron on Saturday with “progress on convening the G-7” among the topics, the White House said. On Friday, U.K. Prime Minister Boris Johnson and Trump “discussed the importance of leaders meeting in the U.S. in person, if possible,” according to Johnson’s office. A Merkel spokesman on Saturday said “she’s unable to confirm her personal participation” given the current state of events.The meeting was planned for Trump’s Doral resort in Florida, was moved to Camp David then became a video conference because of the pandemic. Trump is pushing the G-7 leaders to travel to the U.S. for an in-person meeting.U.S. Cases Rise 1.7%, Above Week’s Average (4 p.m. NY)U.S. cases increased 1.7% from the same time Friday, to 1.76 million, according to data collected by Johns Hopkins University and Bloomberg News. The national increase exceeded the average daily increase of 1.3% for the past week and was the biggest percentage rise since May 22. Deaths climbed 1.2% to 103,389.New York reported 1,376 new cases, for a total of 369,660, with 67 deaths -- the same as Friday and the fifth day of fatalities under 75. Deaths totaled 23,848.New Jersey had 910 new cases, pushing the total to 159,608, with 113 new deaths for a total of 11,634, Governor Phil Murphy reported.California reported 2,992 new cases, for a total of 106,878, and added 88 deaths, with the fatality count at 4,156.Pennsylvania reported 680 new cases, for a total of 71,415, and 73 new deaths, to total 5,537, the state health department said.Florida’s cases rose 1.7% to 55,424 and deaths rose to 2,447, the health department said.Greece Allows More Flights from Mid-June (3:30 p.m. NY)Greece will allow visitors from more nations, including the U.S. and U.K., to arrive at Athens and Thessaloniki airports starting June 15, the Foreign Ministry said. After July 1, flights can land at all Greek airports.The government will use the European Union Aviation Safety Agency’s list of airports to determine testing for arriving passengers. If travel originates at an airport not on the affected-area list, then visitors are subject to random tests, the Foreign Ministry said. If the journey begins at an airport on the EASA list, then visitors who test negative will self-quarantine for seven days and if positive will be under supervised quarantine for 14 days.Greece will reopen borders with Albania, Bulgaria and North Macedonia on June 15, the Foreign Ministry said with visitors subject to random tests. Arrivals by sea will begin July 1.French Cases Inch Higher (2:10 p.m. NY)France reported 57 new deaths, raising the total to 28,771, based on hospital data, with reporting of nursing-home fatalities delayed to Tuesday. New cases climbed by 1,828, or 0.8%, to 225,898.FDA Authorizes Siemens Antibody Test (2:10 p.m. NY)Siemens Healthineers AG received U.S. Food and Drug Administration emergency use authorization for a coronavirus antibody test, used to identify recent or prior infection in humans. The company had expected the test to be available by late May and aims to produce more than 50 million tests a month starting in June.N.Y. Targets NYC ‘Hotspots’ (2 p.m. NY)Governor Andrew Cuomo said the state plans to get New York City reopened by focusing on “hotspots” -- neighborhoods where positive cases can be nearly 50% and are largely in minority communities. The city average rate is about 20%.“We have work to do but we’ll still get it done by June 8,” he said.Cuomo also signed a law to compensate the families of hundreds of essential workers who have died in the outbreak.Italy Cases on Declining Trend (12:01 pm NY)Italy reported 416 new cases, up from 516 a day earlier, confirming a declining trend as the total reached 232,664. Total deaths rose to 33,340. The government confirmed plans to allow travel between regions starting June 3 even as some regional governors opposed letting people from the hard-hit Lombardy region move freely.N.Y. Daily Deaths Unchanged (11:45 a.m. NY)New York reported 67 new deaths, Governor Andrew Cuomo said at a Saturday press conference. The figure is the same as reported on Friday and the fifth straight day below 75 fatalities. The state reported 1,376 new cases, for a total of 369,660.U.K. Permits Live Sports Events (11:30 a.m. NY)The U.K. will allow live sports events, without spectators, and further relax restrictions on physical exercise starting Monday as the country eases lockdown measures.Horse racing will be allowed behind closed doors, with other sports like soccer, rugby, cricket, golf and snooker to follow, but without fans, Culture Secretary Oliver Dowden said at a press conference. “British sports recovery has begun,” Dowden said.England’s Premier League plans to resume matches on June 17, after consulting with the clubs, players and managers, Chief Executive Richard Masters said after the government announcement.Spain Deaths Rise (11:25 a.m. NY)The Spanish health ministry said total coronavirus cases increased by 271 to 239,228 in the past 24 hours. Total fatalities rose to 27,125 with 43 new deaths reported in the past seven days.Somalia Votes in 2021, Despite Outbreak (10:30 a.m. NY)Somalia will push ahead with elections in early 2021, Prime Minister Hassan Ali Kheyre said after a cabinet meeting, removing doubt that the spread of Covid-19 will delay the vote.The Horn-of-Africa nation is seeking debt relief as the pandemic adds to its woes, from an insurgency to locusts. It has almost 2,000 cases and a health system ill-equipped to handle the outbreak.South Africa Allows Domestic Flights (10:20 a.m. NY)South Africa will permit air travel from four main airports starting Monday as the nation eases lockdown measures. Limited domestic flights will be allowed for business, and passengers must give a reason, Transport Minister Fikile Mbalula said in a televised briefing on Saturday.India to Ease Lockdown in Stages (8:52 a.m. NY)India announced a phased lifting of the nationwide lockdown by allowing malls, restaurants and places of worship to open from June 8, the interior ministry said in a statement.The country, which had enforced sweeping and strict stay-at-home orders from March 25, will limit the stringent rules to areas that have a large number of active cases. Authorities will decide to open schools and colleges in July, while international air travel will resume in the final phase. The exit plan comes even as India has been unable to flatten its curve despite the restrictions which have left its already troubled economy in deep disrepair.EU Urges U.S. to Reconsider WHO Decision (8:24 a.m. NY)The European Union called on the U.S. to reconsider its decision to terminate its relationship with the World Health Organization, which President Donald Trump has accused of being too deferential to China.“Global cooperation and solidarity through multilateral efforts are the only effective and viable avenues to win this battle the world is facing,” according to a joint statement Saturday from European Commission President Ursula von der Leyen and the bloc’s chief foreign envoy, Josep Borrell. “We urge the U.S. to reconsider its announced decision.”Portugal’s Virus Cases Slow (8:04 a.m. NY)Portugal reported 257 new coronavirus cases on Saturday, taking the total to 32,203, after recording more than 300 infections in each of the two previous days, the government said. The increase in new cases has been mostly in the greater Lisbon area and led the government on Friday to delay the planned reopening of malls in that region. The number of cases in intensive care units fell to 63 on Saturday, remaining at the lowest level since March.Macau’s Economy Shrinks by Almost Half (6:46 a.m. NY)Macau’s economy posted a deeper contraction in the first quarter as lockdown measures introduced to contain the virus outbreak hit revenue from gambling, hotels, and tourism.Gross domestic product in Macau plummeted 48.7% in the first three months of 2020, according to the city’s statistics department. That is the fifth straight quarterly decline.Belgium’s Socialists Propose $41.7 Billion Stimulus (6:14 a.m. NY)Paul Magnette, the head of Belgium’s Socialist party, proposed a 37.6 billion-euro ($41.7 billion) stimulus package to combat the economic toll of the global pandemic, according to an interview with Le Soir. The aid would target catering, cultural and health-care industries, he said.Iran Reports Fewer New Cases (6:12 a.m. NY)Iran’s infection tally rose to 148,950 as the daily number of new cases dropped to 2,282 from 2,819 on Friday, the highest daily number of cases in eight weeks. The virus death toll reached 7,734 with 57 more deaths overnight.S&P Sees Abu Dhabi, Bahrain Economies Shrinking (5:20 p.m. HK)Abu Dhabi’s economy will contract 7.5% this year, S&P Global Ratings said, citing lower oil production and the pandemic.Bahrain’s economy will shrink 5% this year because of low oil prices, although government stimulus measures should provide some support, S&P said. The ratings company expects Bahrain’s economy to rebound in 2021 as oil prices recover and regional activity increases.Indonesia Gears Up for Post-Holiday Return (5:02 p.m. HK)Indonesia’s capital Jakarta is anticipating one million vehicles will enter the city as people return from Eid al-Fitr holidays. Traffic, including motorcycles, is projected to peak from Saturday to Monday, according to a Cabinet Secretariat statement. While the figure is lower compared to the 2.8 million vehicles recorded last year, the flow of so many travelers is raising concern as the nation’s coronavirus cases grow.Indonesia now has the highest coronavirus death toll in Southeast Asia, with 1,573 people succumbing to the disease as of Saturday. New cases have more than doubled in May, with the total reaching 25,773.Uzbekistan Extends Lockdown (3:36 p.m. HK)The Uzbek government has decided to extend lockdown restrictions until June 15. Central Asia’s most populous nation has confirmed 3,513 cases of infection of the coronavirus, with 14 deaths and 2,728 recoveries.Singapore Reports 506 New Cases (3:30 p.m. HK)Singapore reported 506 new infections as of Saturday, according to a statement from its Health Ministry. A vast majority of the additional infections are of work permit-holders who live in foreign workers’ dormitories, according to the statement. The ministry is expected to provide additional details in the evening, it added.Chinese Vaccine Expected to Begin Mass Output This Year (3:25 p.m. HK)A front-running Covid-19 vaccine being developed in China is expected to be available as soon as the end of this year, according to a report published in the official Wechat account of the State-owned Assets Supervision and Administration Commission.The vaccine, jointly developed by the Beijing Institute of Biological Products and China National Biotec Group Co., has completed phase II testing and may be ready for the market at the end of this year or early next year, said the report.The production line for the vaccine will be fully disinfected and closed in preparation for output to start Saturday, and will have a manufacturing capacity of 100 million-120 million vaccines each year.Iran Lifts Restriction on Shopping Hours (2:26 p.m. HK)Iran has lifted a restriction on the operating hours of shopping malls in the latest step of reopening the economy. Meanwhile, all mosques in the country will be open to worshipers for daily prayers three times a day, President Hassan Rouhani said in a national coronavirus taskforce briefing broadcast on state TV.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Why virus stocks are driving market volatility

    Why virus stocks are driving market volatility

    The market’s erratic response to lukewarm medical research for COVID-19 treatment and vaccine candidates isn’t expected to slow down as investors pin their hopes for an economic recovery on the high-risk biotechnology sector.

  • Why Moderna Stock Jumped 10.7% Today
    Motley Fool

    Why Moderna Stock Jumped 10.7% Today

    Shares of Moderna (NASDAQ: MRNA) rose more than 10% on Friday after the biotechnology company announced the commencement of its Phase 2 study for its novel coronavirus vaccine. Moderna said the first participants in each age group of its Phase 2 study have received doses of its experimental COVID-19 vaccine, mRNA-1273. Moderna is seeking to enroll 600 healthy participants, including 300 people aged 18-55 and 300 people older than 55.

  • MarketWatch

    Moderna begins new COVID-19 vaccine study

    Moderna Inc. announced Friday afternoon that the latest study of its potential COVID-19 vaccine has begun. The first participants in each age range have been dosed with its vaccine candidate, known as mRNA-1273, and will receive another dose 28 days later before being followed for 12 months to determine efficacy. The company intends to enroll 600 patients in the study across two age groups, 18 to 55 and older than 55. Moderna previously released limited details about its phase 1 trial of the vaccine, saying that it produced necessary antibodies in some subjects but neglecting to provide full datasets. Moderna stock shot more than 10% higher Friday, with most of those gains coming in the last hour of the session. Shares were largely quiet in after-hours trading, when the announcement was made.

  • Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
    Motley Fool

    Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?

    The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.

  • Are Moderna’s Coronavirus Gains Over?
    Motley Fool

    Are Moderna’s Coronavirus Gains Over?

    Moderna shares have dropped from a record high. Here’s what hurt the stock -- and what could lead to recovery.

  • Here's the Under-the-Radar Biotech That Could Beat Moderna at Its Own Game
    Motley Fool

    Here's the Under-the-Radar Biotech That Could Beat Moderna at Its Own Game

    Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), who has himself been in the limelight in recent months, even singled out the biotech days ago for what he called its "quite promising" COVID-19 vaccine candidate. Moderna has deservedly received a lot of attention from the press and from investors. This under-the-radar biotech just might even beat Moderna at its own game.

  • Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%

    Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%

    Moderna Inc. (MRNA) announced that it has started dosing the first patients in a Phase 2 study with its experimental mRNA-1273 vaccine candidate against the novel coronavirus. Shares shot up 11% to $61.50 on Friday.The Phase 2 study, being conducted by Moderna under its own Investigational New Drug (IND) application, seeks to evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The biotech company plans to enroll 600 healthy participants across two cohorts of adults ages 18-55 years and older adults ages 55 years and above.Earlier this month, Moderna reported “positive” interim clinical data saying that the Phase 1 study of its mRNA-1273 vaccine candidate produced antibodies that would be able to “neutralize” the virus in patients. The company reiterated plans to start the Phase 3 trial in July, subject to the finalization of the clinical trial protocol.The study will be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). Funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA), will support the late-stage clinical development programs, as well as the scale-up of mRNA-1273 manufacturing both at the company’s facilities and that of its strategic collaborator, Lonza Ltd.Since the start of the year, the value of Moderna’s shares has more than tripled.Earlier this month, five-star analyst Cory Kasimov at J.P. Morgan reiterated a Buy rating on the stock with a $66.69 price target, saying that there is still much work to be done, risks to navigate, and a lot we don’t actually know.“Moderna may have a viable product on their hands,” Kasimov wrote in a note to investors. “That said, how to appropriately capture this in MRNA's valuation is a tougher question to answer (especially given all the unknowns around COVID-19 and the ultimate opportunity) and one that we suspect will be a key investor debate going forward.”Overall, Wall Street analysts are bullish on Moderna stock awarding 10 Buy and 2 Hold ratings which add up to a Strong Buy consensus. Despite the recent share rally, the $96.75 average price target still indicates a staggering 57% upside potential from current levels. (See Moderna stock analysis on TipRanks).Related News: Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses; Top Analyst Ramps Up PT To $61 Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July More recent articles from Smarter Analyst: * China’s Tencent In Talks To Buy $200 Million Stake In Warner Music - Report * Quest’s Covid-19 Self-Collection Test Kit Gets FDA Nod For Emergency Use * Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals * Beyond Meat Teams Up With KFC, Pizza Hut In China

  • Investors Are Jumping the Gun on Moderna's Vaccine Results
    Motley Fool

    Investors Are Jumping the Gun on Moderna's Vaccine Results

    Shares of Moderna (NASDAQ: MRNA) were soaring earlier this month when the company released interim results from its mRNA vaccine. Investors were bullish on the possible COVID-19 vaccine, sending the stock to an all-time high of $87. Coronavirus stocks like Moderna are especially volatile surrounding news related to any treatments or vaccines.

  • Why Moderna Stock Is Still Only Good for Speculators

    Why Moderna Stock Is Still Only Good for Speculators

    Speculation surrounding the novel coronavirus has taken over the stock market. Hope for a cure or, better yet, a vaccine, is driving traders into frenzies. Much of the action is centered around Moderna (NASDAQ:MRNA) and MRNA stock.Source: Shutterstock While the company had just $8.3 million in revenue for the March quarter, it entered trade May 29 with a market cap of $20.6 billion.MRNA stock has been on fire for months. In February, the shares cost $18. It was the release of Phase 1 data earlier this month that sent traders into a frenzy. That showed, as expected, that antibodies against the virus were produced in test subjects. The company also said it was rapidly scaling up production.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTraders who had been buying Moderna rumors sold the news. The shares have since fallen from the mid-80's to the mid-50's. Why Moderna?Nothing has gone wrong, from a scientific standpoint. It's just that there are no guarantees Moderna has the winning lottery ticket.There are now 28 different vaccines being researched around the world, with eight in some type of clinical trial. There are vaccines being tested in England, in China and in Australia. Two other publicly traded U.S. companies, Pfizer (NYSE:PFE) and Inovio Pharmaceuticals (NASDAQ:INO), have Covid-19 vaccine candidates in trial. Novavax (NASDAQ:NVAX), Johnson & Johnson (NYSE:JNJ), and Altimmune (NASDAQ:ALT) are all doing pre-clinical work. So are Merck (NYSE:MRK), GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY). * 7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure Moderna just got there first, with the most publicity. It announced funding on Jan. 23. It's working with the National Institute of Allergy and Infectious Diseases (NIAID), headed by the now-famous Dr. Anthony Fauci. It won an invitation to the White House to talk about its candidate, mRNA-1273. Why Not Moderna?The problem is that vaccines are hard. It's not enough to create antibodies against the disease. A vaccine must stop the spread safely across millions or (in this case) billions of doses.Safety is one issue. Four of the 45 people tested in the Phase 1 study developed reactions to the Moderna vaccine. One 29-year old tweeted that he got a 103 degree fever. He said his dose was 10 times what other patients got, and he didn't go to a hospital in fear of triggering "anti-vax" people.Efficacy is a second issue. Only eight of the subjects produced binding antibodies. Only four were sampled for neutralizing antibodies. The level of T-Cell generation, a measure of how the body is attacking the virus, wasn't mentioned.Moderna's own actions are also an issue. The company announced a $1 billion secondary offering right after its Phase 1 results came out. Some executives sold shares within days. Moderna is moving directly into a Phase 3 study, and mass production, while its Phase 1 is still being evaluated.All these actions have raised suspicions among people who know both science and market valuations. The Bottom Line on MRNA StockThis is my fourth piece on Moderna in six months.I was very positive about MRNA stock when it came public in December. Its methodology, using Messenger RNA, impressed me. In April, I called Moderna "the greatest coronavirus speculation." The problem is success against Covid-19 is now built-into the stock price. Success is far from guaranteed. There are many other horses in this race. It's far from clear how profitable this vaccine will be.It's possible mRNA-1273 could be the start of a business that goes on for decades. It's possible that mRNA-1273 proves Moderna's methodology and it becomes one of the world's great companies. It's also possible that mRNA-1273 fails in Phase 3.There are too many known unknowns for me to recommend investing in MRNA stock at its present price. But you're welcome to speculate.Dana Blankenhorn has been a financial journalist since 1978. His latest book is Technology's Big Bang: Yesterday, Today and Tomorrow with Moore's Law, essays on technology available at the Amazon Kindle store. Follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in JNJ. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * The Huge Story for 2020 & Beyond That You Aren't Hearing About * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * The 1 Stock All Retirees Must Own The post Why Moderna Stock Is Still Only Good for Speculators appeared first on InvestorPlace.

  • Moderna Vaccine Unlikely to Revive U.S. Economy, Survey Says

    Moderna Vaccine Unlikely to Revive U.S. Economy, Survey Says

    (Bloomberg) -- Investors think Moderna Inc.’s experimental Covid-19 inoculation wouldn’t be enough to unlock the economy, an Evercore ISI survey showed.The survey of over 100 investors -- more than half of whom specialize in health care -- found there’s a 43% probability that Moderna’s vaccine would be sufficient to set the U.S. economy aright, analyst Joshua Schimmer wrote in a note. Still, a majority expect the next update on mRNA-1273 will be positive and predicted emergency use authorization will be granted in the fourth quarter and regulatory approval in 2021.Investors pegged the probability at 70% that a better potential vaccine emerges within the next year. There’s no shortage of candidates with at least 10 kicking off human testing and more than 100 others in earlier stages of development, according to World Health Organization estimates. In the near-term, heavy-hitter Pfizer Inc. and its Mainz, Germany-based partner BioNTech SE are expected to have their first results, as is Inovio Pharmaceuticals Inc.Criticism of the first look at Moderna’s vaccine data has been mounting and pessimism about the potential for a broadly used vaccine has tamped down some of the more heady stock gains among companies racing to stymie the spread of Covid-19. As less sophisticated investors propped up Moderna’s stock it became the least profitable short in all of biotech, according to S3 Partners data showing investors lost $1.14 billion through last week.Love to HateLess than a third of respondents said they held a notable position in Covid-19 stocks in their portfolios.Evercore’s survey confirmed that Moderna is the stock specialists love to hate right now with 38 naming it their top short. Second place went to Inovio with eight votes, and Novavax Inc. came in third with six. Novavax, which has rallied more than 1,000% this year, kicked off human testing on Monday. Still 12 investors also picked Moderna as their top long, while BioNTech, AstraZeneca Plc and Pfizer all had six or more votes apiece.And now as the country slowly starts to reopen and the pace of the pandemic eases in some key hotspots, a new concern is emerging, if patients in vaccine trials can be exposed to the virus fast enough to see results.So far that’s not stopping new studies from starting or some investors from stepping in. Dynavax Technologies, which is expected to begin a trial this summer, jumped after Bain Capital bought 1 million shares. Optimistic commentary from partner Sinovac Biotech Ltd. added to a Dynavax stock, which rose as much as 37% on Friday(Updates Dynavax shares)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Why Moderna Stock Rose Today
    Motley Fool

    Why Moderna Stock Rose Today

    Shares of Moderna (NASDAQ: MRNA) climbed 6.4% on Thursday after the biotechnology company said that it extended a manufacturing agreement with a key supplier for its experimental coronavirus vaccine. Global pharmaceutical manufacturing platform CordenPharma will supply Moderna with "large-scale volumes" of lipids for its COVID-19 vaccine candidate, mRNA-1273. "The expanded agreement will begin immediately in order to rapidly meet Moderna's increasing demand over the upcoming months, with an emphasis on securing their future long-term supply," CordenPharma said in a press release.

  • ‘It would be extremely optimistic’ to see a vaccine by the end of the year: John Hopkins Infectious Diseases Expert
    Yahoo Finance Video

    ‘It would be extremely optimistic’ to see a vaccine by the end of the year: John Hopkins Infectious Diseases Expert

    U.S. cases for coronavirus reached more that 1.69 million, with at least 100,442 deaths from the virus. Dr. Amesh A. Adalja from Johns Hopkins’ Center for Health Security joins The Final Round to discuss the latest about the coronavirus, reopening the United States and the vaccine race.


    Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

    When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.


    Moderna Stock Is Giving Investors a Wild Ride. Blame It on Shifting Covid-19 Vaccine News.

    In the 18 trading days so far this May, shares of the biotech have fallen more than 8% on four of them and risen more than 8% on another four. What’s behind the volatility?

  • Moderna Expands Deal With CDMO To Source Raw Material For Coronavirus Vaccine

    Moderna Expands Deal With CDMO To Source Raw Material For Coronavirus Vaccine

    Moderna Inc (NASDAQ: MRNA) is progressing rapidly in its program to develop an mRNA vaccine for SARS-CoV-2, codenamed mRNA-1273.What Happened The Luxembourg-based contract development and manufacturing organization Corden Pharma announced Thursday an amendment to its existing manufacturing agreement with Moderna that will enable it to manufacture large-scale volumes of the latter's lipid excipients to be used in the making of mRNA-1273.The manufacturing will be done by CordenPharma facilities in France and Colorado. The expanded agreement comes into force immediately in order to rapidly meet Moderna's increasing demand over the coming months, CordenPharma said.The original agreement was signed between Modern and CordenPharma Switzerland in 2016.Why It Matters Moderna released positive interim Phase 1 data earlier this month from a NIAID-sponsored trial, showing dose-dependent increases in immunogenicity across three dose levels and between prime and boost within the 25-microgram and 100-microgram dose levels of RNA-1273.The company is expected to commence a Phase 2 study shortly, having had its IND cleared by the FDA. The company is also planning to initiate a Phase 3 study in July.Moderna's vaccine candidate is touted to be one of the likeliest vaccines in development to move past the finish line.At last check, Moderna shares were rising 7.85% to $56.28.Related Links:The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer The Week Ahead In Biotech: ASCO Presentations In The Spotlight See more from Benzinga * Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race * Moderna Analyst Says Coronavirus Vaccine Candidate Has 65% Chance Of Success * Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • FIRST FIRM TO INVESTIGATE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm

    FIRST FIRM TO INVESTIGATE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / May 28, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of the securities laws. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

  • How Novavax is pulling out all the stops to produce a coronavirus vaccine by next year
    Yahoo Finance

    How Novavax is pulling out all the stops to produce a coronavirus vaccine by next year

    If all goes according to plan, Novavax anticipates being able to produce 100 million doses in 2020, mostly for frontline workers, and 1 billion doses by 2021.

  • TradeZero America Co-founder on investor trends during market volatility
    Yahoo Finance Video

    TradeZero America Co-founder on investor trends during market volatility

    Dan Pipitone, co-founder of TradeZero America, joins The Final Round to discuss what the platform is seeing in the wake of COVID-19 and trends among investors.

  • Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
    PR Newswire

    Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.

  • Moderna extends lipids deal to boost COVID-19 vaccine candidate output

    Moderna extends lipids deal to boost COVID-19 vaccine candidate output

    The company on Thursday signed an agreement with Swiss firm CordenPharma for the supply of large-scale volumes of lipid excipients used to produce its vaccine candidate. Moderna said last week that its vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, offering a glimmer of hope for a vaccine among the most advanced in development. "This expansion will increase supply of lipid excipients used to manufacture our mRNA products," Moderna's chief technical operations and quality officer, Juan Andres, said.

  • CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2
    CNW Group

    CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2

    CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2